Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05701527 · ClinicalTrials.gov registry record · Phase 1
A Study of EBC-129 in Advanced Solid Tumours
A Phase 1 study of Advanced Solid Tumours, sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 5
- Study locations
NCT05701527 is a Phase 1 study of Advanced Solid Tumours that is actively recruiting participants, run by EDDC (Experimental Drug Development Centre), A*STAR Research Entities. The registered enrollment target is 98 participants, below the 227-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (57% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05701527, a Phase 1 study of Advanced Solid Tumours, is actively recruiting participants, sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG EBC-129
Study Locations (5)
South West
- National University Hospital - Medical Oncology - Singapore
- National Cancer Centre Singapore - Singapore
Colorado
- University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center - Aurora
Texas
- UT MD Anderson Cancer Center - Houston
Taipei
- Taipei Veterans General Hospital - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2026-12-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05701527
The ClinicalTrials.gov registry entry for NCT05701527 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (57% lower). The listed sponsor is EDDC (Experimental Drug Development Centre), A*STAR Research Entities, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05701527 reports 5 study locations spanning 4 distinct geographic areas - top geographies include South West, Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT05701527 about?
NCT05701527 is a clinical study titled "A Study of EBC-129 in Advanced Solid Tumours". This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
What is the current status of trial NCT05701527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-04-28. Estimated completion is 2026-12-24.
What conditions does trial NCT05701527 study?
This clinical trial studies the following conditions: Advanced Solid Tumours.
What interventions are being tested in trial NCT05701527?
The interventions under investigation include: Pembrolizumab (DRUG), EBC-129 (DRUG).
Who is sponsoring clinical trial NCT05701527?
This trial is sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05701527 being conducted?
This trial has 5 study locations across Colorado, Texas, South West, Taipei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
RECRUITING · Phase 1
-
First in Human Study of AZD9592 in Solid Tumors
RECRUITING · Phase 1
-
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.